Aponermin

埃普奈明

Report date: 2025/02/26 16:24:26

Base Information

Drug NameAponermin
Drug Alias Name注射用重组变构人肿瘤坏死因子相关凋亡诱导配体CPTCircularly permuted TRAILRecombinant human tumor necrosis factor-related apoptosis-inducing ligandRecombinant Apo2L +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionTumor necrosis factor receptor superfamily member 10B agonistsTumor necrosis factor receptor superfamily member 10A agonists
TargetsTumor necrosis factor receptor superfamily member 10BTumor necrosis factor receptor superfamily member 10A
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaMultiple Myeloma
Original Approved Country/TerritoryMainland China
Original Approved Date2023/11/02
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeijing Shadong Biotech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWuhan Hiteck Biological Pharma Co Ltd
Inactive CompaniesInstitute Of Hematology & Blood Diseases HospitalBeijing Shadong Biotech Co Ltd
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A